source
- Zanidatamab shows strong single-agent activity in HER2-positive gastric and biliary cancersZanidatamab, a dual HER2-binding antibody, demonstrated notable efficacy as a single agent in studies of gastric and biliary tract cancers. The activity was described as striking, suggesting that…
- Astellas reports promising early results for stem cell eye therapy ASP7317 in age-related diseaseAstellas announced data from an early-stage trial of ASP7317, a stem cell-derived therapy aimed at an age-related eye condition. The study showed encouraging signs of efficacy and safety in most p…